GSK provides update on corporate responsibility commitments in 2011 report
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has published its Corporate Responsibility Report, in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Abbott's investigational treatment for advanced Parkinson's disease demonstrates positive results
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).
Roche on track for full-year targets - good sales growth in first quarter
- Details
- Category: Roche
In the first three months of 2012 Group sales rose 2% in constant currencies to 11.0 billion Swiss francs. The Pharmaceuticals Division's sales increased 2% to 8.6 billion Swiss francs. Excluding Tamiflu, sales for the Group and Pharma rose 3%.
Takeda to Acquire URL Pharma
- Details
- Category: Takeda
Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma - a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.
UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™
- Details
- Category: UCB
UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map™ is a visual tool designed to help people with PD discuss their health status and well-being with their care teams.
Amgen to acquire privately held KAI Pharmaceuticals
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.
Open-source drug research consortium draws a major new champion
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. The SGC is based at the Universities of Toronto, Canada, and Oxford, England.
More Pharma News ...
- Roche sends second letter to Illumina shareholders
- Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
- Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome
- Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio
- Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines
- Bayer HealthCare and Beijing's Tsinghua University extend innovative drug discovery partnership
- Sanofi and Regeneron report phase 2 data for potential first-in-class lipid-lowering PCSK9 antibody